Epidermal growth factor receptor (EGFR) had been reported as one of the major responsible genes for malignant progression and phenotype reversion of gliomas, and has been used as one of the most important therapeutic targets. In the present study, small interference RNA (siRNA) and antisense EGFR expression constructs, which target sequences of human EGFR catalytic domain (2400-2420) and the 3 0 -coding region, respectively, were used to examine the growth inhibition effects on U251 glioma cells. Cell growth was significantly inhibited and G2/M arrest was observed in antisense-and siRNA-treated groups. Matrigel matrix demonstrated spotted cell clustering pattern in antisense-and siRNA-transfected U251 cells, indicating poor cell growth activities. In addition, the tumor volumes in U251 subcutaneous mice model treated with antisense and siRNA were significantly smaller than those treated with control siRNA and phosphate-buffered saline. Also, glial fibrillary acidic protein expression was upregulated in antisense-and siRNA-treated groups than the control groups. Our results demonstrated that antisense-or siRNA-targeting intracellular region of EGFR can inhibit EGFR expression, exerted growth inhibition effect on U251 glioma cells in vitro and in vivo. Consequently, siRNA expression plasmid-mediated gene therapy would be a new strategy in treatment of gliomas.
Introduction
Gliomas are the most common primary tumors in the brain. Current therapeutic modalities include surgical resection, radiosurgical/external irradiation, chemotherapy and biological therapy. However, most patients with high-grade gliomas (anaplastic gliomas and glioblastoma multiforms (GBMs)) receive radiation and chemotherapy regardless of the extent to which the visible tumor has been removed. For a recurrent malignant glioma, surgery might be carried out if the risk and benefit of such an operation are favorable based on the location and conditions of the patients, and further radiation is conventionally recommended. In a meta-analysis of 12 randomized clinical trials, the overall survival rate of high-grade gliomas was 40% at 1 year and only slightly higher (46%) after combined radiotherapy and chemotherapy. 1 Clinically, less than 3% of glioblastoma patients are still alive 5 years after diagnosis, older age being the most significant predictor of poor outcome.
GBMs can arise de novo or progress from lower to higher grade and possess a series of genetic alterations and dynamic progressions, which have been identified to be correlated with the molecular pathology of GBMs. Epidermal growth factor receptor (EGFR) has shown to be overexpressed in a variety of tumors and is one of the important mediators responsible for the development of high-grade gliomas, especially in primary glioblastomas. 2, 3 Genetic studies have demonstrated that the EGFR gene aberration is the most frequent predominant event in high-grade gliomas, is commonly (40-60%) amplified up to hundreds of gene copies in glioblastomas (especially of the aggressive de novo type) and is associated with high levels of EGFR mRNA or protein expression. 4 Antisense approach targeting EGFR could inhibit significantly not only the EGFR expression but also the cell proliferation of malignant glioma either in vitro or in vivo. 5 Specific inhibitors of the EGFR tyrosine kinase (TK) have been developed and display encouraging potentials in cancer therapy.
6 ZD1839 (gefitinib), a EGFR TK inhibitor administered post orally, has been demonstrated to have in vitro efficacy against glioma, lung, colorectal, prostate, ovarian, and breast cell lines and cause in vivo growth delay in a range of subcutaneous human tumor xenografts that express EGFR. 7 However, increasing evidences have suggested that EGFRvIII may not be susceptible to gefitinib in NR6M tumors. 8 Another study has also demonstrated that EGFRvIII glioblastomas required higher doses, repeated dosing, and longer exposure in order to decrease its receptor phosphorylation, and such a decrease did not effectively inhibit the biologically relevant processes of DNA synthesis, cellular growth, and invasion in cells expressing EGFRvIII. 9 In a Phase II trial of gefitinib in recurrent glioblastoma, the median survival time was 39 weeks and no objective tumor responses were observed in 53 patients with recurrent glioblastoma treated with gefitinib orally. 10 Therefore, EGFR may be involved in the most important molecular event in GBMs, and it represents a valuable target for gene therapy of high-grade gliomas.
RNA interference (RNAi) has been widely used to induce sequence-specific degradation of the targeting mRNA. The double-stranded RNAs are processed into small interfering RNAs (siRNAs) and mediate the suppression of homologous genes through a phylogenetically conserved cellular pathway via a two-step mechanism. [11] [12] [13] RNAi technology has been demonstrated to silence the targeted gene expression more efficiently and specifically, as compared to antisense approach. [14] [15] [16] The application of RNAi towards signaling molecules active in cancer has recently been shown to ameliorate the transformed phenotype in various tumors. In the present study, we report that using both antisense and siRNA approach to suppress the EGFR expression, through targeting the intracellular TK domain, can inhibit the U251 tumor growth in vitro and in vivo.
Materials and methods
Antisense and siRNA constructs The EGFR cDNA in pactQsR3 was kindly provided by Dr Laura Beguinot, Italy. 17 The antisense orientation of EGFR cDNA fragment (552 bp), complementary to the 3 0 -coding region of EGFR mRNA, was double digested by XbaI/XhoI and subcloned into pcDNA3, which was named as panti-EGFR. For siRNA construct, one target sequence (5 0 -AG GAATTAAGAGAAGCAACAT-3 0 ) was selected corresponding to the open reading frame of human EGFR gene (NM-005228) and named as psiRNA-EGFR. The construct containing scrambled sequence (5 0 -GCAG CAACTGGAGGATCTAGA-3 0 ) was also included as a negative control and named as psiRNA-scr ( Figure 1 ) as previously described. 18 Cell culture and transfection Human glioblastoma U251-MG cells were obtained from Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heatinactivated fetal calf serum, 4 mM glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin. For gene transfection, 2 Â 10 5 cells per well were plated into six-well plates and grown overnight until they were 50-80% confluent. Plasmids panti-EGFR, psiRNA-EGFR and psiRNA-scr (2 mg each) were transfected into U251 cells by lipofectamine as instructed by the manufacturer. Cells were subcultured at a 1:5 dilution in 300 mg/ml G418-containing medium. Positive stable transfectants were selected and expanded for further study.
Semiquantitative RT-PCR
The total RNA was extracted using TRIzol reagents (Life Technologies), according to the manufacturer's instructions. Isolated RNA was electrophoresed through 1.0% agarose-formaldehyde gels to verify the quality of the RNA. The first strand cDNA was generated from 1 mg of total RNA in a final volume of 20 ml using SuperScript II (Life Technologies) and oligo (dT) primers.
PCR amplification was performed using a PerkinElmer DNA thermal cycler (PTC-200). The sequences of PCR primers were: EGFR, 5 0 -AGCCATGCCCGCATT AGCTC-3 0 and 3
0 -TCCCTGGAGAAGAGCTACGA-3 0 and 3 0 -TGCTCCTTCAGGACATGGACT-5 0 . To determine the expression level of EGFR, 1 ml (out of 20 ml) of synthesized cDNA was amplified in a total volume of 50 ml containing 200 mM each of all four dNTPs, 2 mM each of EGFR primers, and 1 U of Taq DNA polymerase (TAKARA BIO). PCR conditions were as follows: 941C, 30 s; 561C, 30 s; 721C, 90 s; 30 cycles, finally extending at 721C for 5 min. The b-actin was used as a loading control. PCR products were analyzed by electrophoresis through 2% agarose gel containing 0.1 mg/ml of ethidium bromide.
Western blotting analysis
After G418 selection, individual clones were trypsinized and washed with ice-cold phosphate-buffered saline (PBS) three times. Then the cells were solubilized in 1% Nonidet U251 glioma cell growth C-S Kang et al P-40 lysis buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 1% Nonidet P-40, 10% glycerol, 1 mM CaCl 2 , 1 mM MgCl 2 , 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium fluoride, 1 mM sodium orthovanadate, and a protease inhibitor mixture. Homogenates were clarified by centrifugation at 20 000 g for 15 min at 41C and protein concentrations were determined using a bicinchoninic acid protein assay kit (Pierce). Samples were adjusted to equal protein concentration and volume, and subjected to SDS-PAGE on 8% SDS-acrylamide gel. Separate proteins were transferred to PVDF membranes (Millipore, USA) followed by blocking. The membranes were incubated with primary antibody against EGFR (1:100 dilution, Santa Cruz Biotechnology), followed by incubation with HRP-conjugated secondary antibody (1:1000 dilution, Zymed). The specific protein was detected using a SuperSignal protein detection kit (Pierce, USA). After washing with stripping buffer, the membrane was reprobed with antibody against b-actin (1:500 dilution, Santa Cruz Biotechnology) using the same procedures described above.
Flow cytometric analysis
After G418 selection for 4-5 weeks, the transfected cells and control cells in the log phase of growth were harvested by trypsinization for flow cytometric analysis. After cells were washed with PBS, fixed with ethanol and incubated with RNase at 371C for 30 min. Nuclei of cells were stained with propidium iodide for additional 30 min. Total of 10 000 nuclei were examined in a FACS Caliber flow cytometer (Becton-Dickinson, Heidelberg, Germany) and DNA histograms were analyzed by Modifit software.
In vitro growth on matrigel matrix
Transfected and control cells in the log phase of growth were washed in medium and seeded in duplicate in 24-well plates (1 Â 10 5 cells per well), precoated with 250 ml matrigel basement membrane matrix (Becton Dickinson). After incubation for 36 h, photographs were taken at Â 10 magnification with an Olympus camera attached to an IX70 inverted phase-contrast microscope.
MTT assay
Growth inhibition of psiRNA-EGFR was evaluated using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT, Sigma) assay. Briefly, 1 Â 10 4 cells were plated in 96-well plates and grown overnight. In all 20 ml MTT (5 g/l) was added into each well for 4 h. After the medium containing MTT was aspirated, the formazan crystals were dissolved in 200 ml of dimethyl sulfoxide (DMSO). The absorbance was recorded using a Teacan 96-well spectrophotometer at wavelength of 570 nm, with wavelength of 630 nm as the reference. The data are presented as the mean7s.d., derived from triplicate samples of at least three independent experiments.
Transwell invasion assay
The transwell filters (Costar, USA) were coated with matrigel (3.9 mg/ml, 60-80 ml) on the upper surface of polycarbonic membrane (diameter 6.5 mm, pore size 8 mm). After incubating at 371C for 30 min, matrigel became solidified and served as the extracellular matrix for tumor cell invasion analysis. Harvested cells (1 Â 10 5 ) in 100 ml of serum-free DMEM were added into the upper compartment of the chamber. A total of 200 ml conditioned medium derived from NIH3T3 cells was used as a source of chemoattractant and placed in the bottom compartment of the chamber. After 24 h of incubation at 371C with 5% CO 2 , the medium was removed from the upper chamber. The noninvaded cells on the upper side of the chamber were scraped off with a cotton swab. The cells that had migrated from matrigel into the pores of the inserted filter were fixed with 100% methanol, stained with hematoxylin, mounted and dried at 801C for 30 min. The number of cells invading through the matrigel was counted using three randomly selected visual fields from the central and peripheral portion of the filter by an inverted microscope at Â 200 magnification. Each assay was repeated three times.
Subcutaneous tumor model and gene therapy
Female immune-deficient nude mice (6 weeks old) (BALB/c-nu) were purchased from the animal center of the Cancer Institute of Chinese Academy of Medical Sciences, bred at the facility of laboratory animals, Tianjin University, and housed in microisolator individually ventilated cages with water and food. All experimental procedures were carried out according to the regulations and internal biosafety and bioethics guidelines of Tianjin Medical University and the Tianjin Municipal Science and Technology Commission.
Four mice were injected subcutaneously with 1 Â 10 8 of U251 cells, in a volume of 50 ml of PBS premixed with equal volume of matrigel matrix (Becton Dickinson). Mice were monitored daily and three out of four mice formed tumor subcutaneously. When the tumor size reached approximately 5 mm in length, the tumors were surgically removed, cut into pieces of 1-2 mm 3 and re-seeded in other 40 mice individually. Again, when the tumor size reached approximately 5 mm in length, the mice were randomly grouped as U251, psiRNA-scr, panti-EGFR and psiRNA-EGFR. In panti-EGFR, psiR-NA-scr and psiRNA-EGFR groups, 10 mg plasmid DNA in 10 ml of lipofectamine were injected into subcutaneous tumors using a multi-site injection manner. Mice in U251 groups received 10 ml of PBS only. Another administration was conducted on the third day in the same way. The tumor volume was measured with a calliper, using the formula volume ¼ length Â width 2 /2.
Immunohistochemistry After 28 days, mice were killed and paraffin-embedded tissue sections were used for examination of EGFR, proliferating cell nuclear antigen (PCNA) and glial fibrillary acidic protein (GFAP) expression. Sections were dewaxed, treated with 3% H 2 O 2 for 10 min and incubated with appropriate antibody (1:200 dilution) overnight at 41C. Biotinylated secondary antibody (1:200 dilution) was added at room temperature for 1 h, followed by the incubation with ABC-peroxidase for additional 1 h. After washing with Tris-buffer, the sections were incubated with DAB (3,3 0 diaminobenzidine, 30 mg dissolved in 100 ml Tris-buffer containing 0.03% H 2 O 2 ) for 5 min, rinsed in water and counterstained with hematoxylin.
Detection of apoptosis
Apoptosis was detected by TUNEL method. Briefly, sections were dewaxed, incubated with blocking solution (0.3% H 2 O in double diluted water) for 30 min, and permeabilized with 0.1% Triton X-100 in PBS for another 2 min on ice. Apoptosis was detected using an in situ cell death kit (Boehringer Mannheim, Germany). Positive cells were visualized by fluorescent microscopy. The reaction mixture was incubated without enzyme in a control coverslide to detect nonspecific staining.
Statistical analysis
A commercially available software package SPSS10.0 was used for statistical analysis. One-way analysis of variance (ANOVA) and w
2 test was used to analyze the significance between groups. The LSD method of multiple comparisons with parental and control vector groups was used when the probability for ANOVA was statistically significant. Statistical significance was determined at Po0.01 level.
Results
Suppression of EGFR expression by antisense and siRNA plasmids in human U251 glioma cells In order to efficiently knockdown the EGFR expression in U251 glioma cells, we used a DNA-based antisense and siRNA approach. In our previous study, two siRNAs oligonucleotides corresponding to extracellular ligandbinding domain and the intracellular TK domain were subcloned into psiRNA-Neo2 plasmid for expressing the short hairpin RNA from the polymerase-III H1 RNA promoter, the siRNA targeting the intracellular TK domain, namely psiRNA-EGFR, demonstrated more effectiveness in knockdown of EGFR expression and the growth inhibition. 18 To compare the antitumor effect of antisense RNA and siRNA targeting the intracellular TK domain of human EGFR, two constructs were prepared and transfected into human U251 glioma cells. After selection for 4 weeks, G418-resistant cells were obtained. As shown in Figure 2 , the morphology of cells in the control vector-transfected group was similar to the parental U251 cells. However, the appearances of glioma cells in the siRNA groups became long and narrow in shape, especially in psiRNA-EGFR-transfected cells (Figure 2) .
Western blotting analysis showed that transfection of control vector had little effect on EGFR expression. However, EGFR expression was dramatically downregulated by approximately 85 and 90% in cells transfected with panti-EGFR and psiRNA-EGFR, respectively ( Figure 2) . Meanwhile, the semiquantitative PCR demonstrated the similar downregulation of EGFR expression that is consistant with results from Western blot analysis. These results suggest that both antisense and siRNA approaches can potently and specifically inhibit the EGFR expression in U251 glioma cells.
Effect of EGFR knocked-down on U251 glioma cell proliferation
The cell cycle distribution of control and transfected cells was analyzed by flow cytometry. As shown in Figure 3a and b, the G2/M phase fraction of parental U251 cells and cells transfected with scrambled vector was 9.6% and 10.8%, respectively, while the percentage of antisense and siRNA plasmid-transfected cells in G2/M phase was increased to 22.7 and 21.3%, respectively. The S-phase fraction in parental U251 cells and cells transfected with scrambled vector was 32.3 and 31.6%, respectively, but decreased significantly in antisense and siRNA plasmidtransfected cells to 19.1 and 17.3%, respectively. The percentage of cells in G0/G1 was not changed in all four groups of cells. These results suggest that both antisense and siRNA approach can induce the arrest of the cells at G2/M phases, delay the progression of cell cycle and inhibit the cell proliferation.
Next, we performed in vitro Matrigel matrix growth to evaluated tumorigenesis of U251 glioma cells after siRNA and antisense transfection. Attached growth pattern represents the normal cell growth, while spotted cell clustering indicates poor cell growth. After 36 h of incubation, the parental U251 cells and cells transfected with scrambled vector had attached to the matrigel matrix and grown well. On the contrary, the psiRNA-scr and psiRNA-EGFR-transfected cells demonstrated the (Figure 3c ). When examing the comparative survival rate by MTT assays, the antisense and siRNAtransfected cells were proliferated at a significantly lower rate than those of scramble vector transfected and parental cells (Figure 3d , Po0.05, from days 3-6), suggesting that downregulation of EGFR may be involved in the regulation of cell proliferation.
Cell invasion assessed by Transwell invasion assay
To further evaluate the anti-invasive activity of U251 glioma cells by antisense and siRNA approach, we assessed the inhibitory effect on glioma cell invasion through Transwell assay. The invasive potential was determined on the basis of the ability of cells to invade a matrix barrier containing mainly laminin and type IV collagen, the major components of the basement membrane. Representative micrographs of Transwell filters are shown in Figure 4a , U251 glioma cells transfected with antisense and siRNA constructs significantly inhibited the invasive activity by approximately 40%, as compared to the parental and psiRNA-scr-transfected cells (Figure 4b) . The result suggests that knockdown the human EGFR expression by antisense and siRNA approach can significantly reduce the glioma cell invasion.
Antitumor effect of EGFR knocked-down on U251 glioma Xenograft model
Our in vitro experiments have demonstrated that both antisense and siRNA approach can efficiently inhibit cell proliferation, induce the G2/M cell cycle arrest and prevent the invasion of U251 glioma cells. Therefore, we further investigate the antitumor effect of such approaches in vivo using U251 glioma xenograft model 3 , respectively, and with no statistically significant difference among the four groups (date not shown). All the mice were monitored every 2 days for 3 weeks, and the tumor volumes were measured and compared (Figure 5a ). The mean volumes of tumors were 7413.40, 6492.07, 2167.97 and 1427.63 mm 3 after treatment with PBS or lipofectamine-mediated gene therapy for psiRNA-scr, panti-EGFR, and psiRNA-EGFR, respectively. EGFR knocked-down resulted in statistically significant reduction (Po0.01) in tumor volumes (29 and 19% for antisense and siRNA, respectively) compared to that of PBS-treated group.
After mice were observed for 28 days, the tumor samples were taken out and paraffin-embedded section were prepared for immunohistopathological examination using anti-EGFR, GFAP and PCNA antibodies. Representative sections from mice treated with PBS or lipofectamine-mediated gene therapy for psiRNA-scr, panti-EGFR and psiRNA-EGFR, were shown in Figure  5b -e. In PBS-and psiRNA-scr-treated groups, strongly positive immunoreactivity of EGFR was observed. However, the expression of EGFR was downregulated by antisense or siRNA gene therapy as shown in Figure 5b . We next examined the excised samples for GFAP expression, an intermediate filament protein predominantly expressed in cells of astroglial origin and also used as a marker for glioma differentiation. Only a little GFAP immunoreactivity was detected in PBS-and psiRNA-scr-treated groups, indicating poor differentiation. On the contrary, upregulation of GFAP expression was detected in antisense-or siRNA-treated groups, suggesting that knockdown the expression of EGFR may result in the GFAP upregulation and transforming phenotypes of U251 glioma cells. TUNEL staining showed that there were nearly no apoptotic cells found in PBS-and psiRNA-scr-treated groups. However, apoptosis was prominently increased in antisense-or siRNA-treated groups, but mostly aggregated in the central area (Figure 5d ). The expression of PCNA was also greatly reduced in tumor tissues derived from antisense-or siRNA-treated groups, as compared with that in PBS-and psiRNA-scr-treated groups (Figure 5e ) (Po0.01, w 2 ¼ 30.93).
Discussion
Gene therapy targeting TK domain in glioma therapy EGFR gene consists of 28 exons and encodes a 170 kDa of glycoprotein, comprising an extracellular region (encoded by exons 1-16), a membrane spanning region (encoded by exon 17) and an intracellular region (encoded by exons [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . 19 The extracellular portion of EGFR is The most common mutation in glioblastomas is the deletion of exons 2-7 (EGFRvIII), which produces an inframe deletion of amino acids 6-273 in a portion of subdomain I and all of subdomain II in the extracellular region of the protein. 21 This variant produces a unique functional peptide, and renders the EGFR unable to bind any known ligand, while harboring constitutive kinase activity independent of ligand binding. 22 Despite this, glioma cells transfected with EGFRvIII have enhanced tumorigenicity when grown as xenografts in nude mice. 23 Therefore, targeting the EGFR may present a valid therapeutic intervention. However, the use of EGFR inhibitors in the treatment of glioma, while promising, remains problematic. 8, 9 Published report has indicated that siRNA directed against the unique exon 1/exon 8 junction sequence of EGFRvIII can efficiently suppress its expression in human glioblastoma cell lines, leading to the reduction of the levels of phosphorylated Akt as well as the induction of partial arrest at the G2/M phase of the cell cycle. 24 Taken together, the increased expression of EGFR and the key role that this receptor may play in glioma development and progression led to the investigation of targeting EGFR for anticancer therapies.
Biological changes by silenced EGFR expression
A number of previous studies have demonstrated that EGFR may be a good candidate for anticancer target in human gliomas. The antisense, dominant-negative or EGFR TK inhibitor could effectively inhibit tumor growth, induce apoptosis and cell cycle arrest, and enhance the radiosensitization of gliomas. [25] [26] [27] [28] Using an antisense construct complementary to the 3 0 -coding region of EGFR mRNA (AS-3 0 ,552 bp), Pu et al. 25 have demonstrated that exogenous antisense EGFR cDNA can successfully inhibit proliferation and induce apoptosis in C6 glioma cells in vitro, and stereotactically delivery of lipofectin-mediated antisense construct can prolong survival time of tumor-bearing rats. In addition, studies by Ng have demonstrated that antisense EGFR construct transfected into U87 glioma cell can impair the proliferation, reduce the soft agarose growth activities, induce G0/G1 arrest, and upregulate the expression of GFAP. 26 Most recently, we have demonstrated that the interruption of EGFR signaling pathway by plasmid-based RNAi can inhibit the proliferation and invasion of TJ905 glioma cells, meanwhile, siRNA gene therapy targeting EGFR can induce G0/G1 cell cycle arrest. 18 Another study has reported that the increased invasiveness and gelatinase activity in C6 glioma cells are associated with the increase of PI3-K activity, an important downstream signaling target of EGFR, as demonstrated by LY294002, a specific PI3-K inhibitor, can inhibit the activation of Akt, expression of MMPS and the cell invasion in C6 glioma cells. 29 An U6 promoter-based RNAi gene therapy targeting PI3-K b110 subunit can inhibit U251 growth, induce apoptosis, G2/M cell cycle arrest and suppress tumor cell invasion (unpublished date). Thus, signal transduction pathways downstream of EGFR have been found to be critical in mediating important cellular functions, including survival, proliferation, migration, and invasion; inhibition of overexpressed and/or activated EGFR/PI3-K-mediated signaling pathways possess great significance in malignant glioma gene therapy. 30 Use of siRNA gene therapy for glioma During last 4 years, RNAi has been rapidly developed from an interesting biological phenomenon to one of the most widely used tools in modern biology. However, there is still long way to put siRNA therapy into clinical practice. First, only a limited number of target sequences appear to be capable of producing highly effective RNAi in mammalian cells, there is no universal guidelines for sequence selection in siRNA study. 31, 32 Reynolds has proposed eight characteristics for siRNA target sequence identification: low G/C content; a bias towards low internal stability at the sense strand 3 0 -terminus; lack of inverted repeats; and sense strand base preferences (positions 3, 10, 13 and 19). 33 Since accessibility of the siRNA may depend on the secondary structure of the target mRNA, Kumiko et al. propose a guideline for selection of highly effective siRNA sequences for mammalian cells: A/U at the 5 0 end of the antisense strand; G/C at the 5 0 end of the sense strand; at least five A/U residues in the 5 0 terminal one-third of the antisense strand; and the absence of any GC stretch of more than 9 nt in length. 34 Whether these guidelines are suitable for siRNA target sequence selection needs further investigation.
The therapeutic application of siRNA, however, is largely dependent on the development of a delivery vehicle that can efficiently deliver the siRNAs to target cells. In addition, such delivery vehicle should be administered efficiently, safely, and repeatedly. Cationic liposome-mediated intravenous and intraperitoneal delivery can transport siRNAs into various cell types. 35 Muratovska has used membrane permeable peptides conjugated to siRNA to successfully deliver of siRNA with better delivery characteristics than cationic liposomes. 36 Recently, Pardridge and his co-workers have developed a new siRNA delivery system with doubly conjugated pegylated immunoliposome to treat intracranial U87 glioma mice intravenously. Weekly administration of RNAi gene therapy targeting EGFR can reduce the EGFR expression in tumor sample and achieve 88% increase in survival time in tumor-bearing mice. 37 Using this approach, it seems that siRNA can be delivered across the blood-brain barrier into glioma. Thus, future studies are warranted to test the silence efficacy of various target genes of EGFR pathways, to develop targeting gene delivery system that can cross the blood-brain barrier is also in need.
